Skip to main content
ACS Pharmacology & Translational Science logoLink to ACS Pharmacology & Translational Science
. 2021 May 4;4(3):1247. doi: 10.1021/acsptsci.1c00113

Correction to “Target-Driven Design of a Coumarinyl Chalcone Scaffold Based Novel EF2 Kinase Inhibitor Suppresses Breast Cancer Growth In Vivo

Ferah Comert Onder, Nermin Kahraman, Esen Bellur Atici, Ali Cagir, Hakan Kandemir, Gizem Tatar, Tugba Taskin Tok, Goknur Kara, Bekir Karliga, Serdar Durdagi, Mehmet Ay , Bulent Ozpolat
PMCID: PMC8205232  PMID: 34151214

The corrections of misnumbered refs citations in the main text for refs 36–55 are given below. The changes in the reference list have not affected any conclusions reached in the paper.

  • On p 928, citations for refs 42 and 47 should be 36 and 37, respectively.

  • On p 928, citations for refs 48–49 should be 38–40.

  • On p 930, the citation for ref 50 should be ref 41.

  • On p 934, citations for refs 51, 37, 52, and 53 should be 42, 43, 44, and 45, respectively.

  • On p 936, the citation for ref 47 should be 37.

  • On p 936, citations for refs 50, 54, 55, 42 should be 41, 46, 47, 36.

  • On p 936, citations for refs 45–38 should be 48–50.

  • On p 936, the citation for ref 47 should be 37.

  • On p 936, citations for refs 39,40 should be 51,52.

  • On p 936, citations for refs 43–41 should be 53–55.

  • On p 936, citations for refs 43,44 should be 53,54.

  • On p 937, the citation for ref 46 should be 45.

  • On p 937, citations for refs 47,53 should be 37,45.

  • On p 937, citations for refs 16,53 should be 16,45.

  • On p 937, the citation for ref 53 should be 45.


Articles from ACS Pharmacology & Translational Science are provided here courtesy of American Chemical Society

RESOURCES